Theravance Biopharma (TBPH) Change in Accured Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has reported Change in Accured Expenses for 14 consecutive years, with -$4.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 221.47% year-over-year to -$4.9 million; the TTM figure through Mar 2026 stood at $656000.0 (down 80.42% YoY), while the FY2025 annual figure was $4.0 million, up 173.09% from the prior year.
• Change in Accured Expenses slipped to -$4.9 million in Q1 2026 per TBPH's latest filing, from -$1.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $17.2 million in Q4 2022 and bottomed at -$10.3 million in Q1 2022.
• Historically, Change in Accured Expenses has averaged -$454764.7 across 5 years, with a median of -$791000.0 in 2022.
• On a YoY basis, Change in Accured Expenses climbed as much as 2740.95% in 2022 and fell as far as 665.25% in 2022.
• Theravance Biopharma's Change in Accured Expenses stood at $17.2 million in 2022, then tumbled by 102.54% to -$438000.0 in 2023, then jumped by 782.88% to $3.0 million in 2024, then slumped by 142.63% to -$1.3 million in 2025, then slumped by 281.73% to -$4.9 million in 2026.
• Business Quant data shows TBPH's Change in Accured Expenses at -$4.9 million in Q1 2026, -$1.3 million in Q4 2025, and $3.6 million in Q3 2025.